Willy A Flegel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3176618/publications.pdf

Version: 2024-02-01

244 papers

7,912 citations

51 h-index 69214 77 g-index

255 all docs 255 docs citations

times ranked

255

3506 citing authors

#	Article	IF	CITATIONS
1	Recommendation for validation and quality assurance of nonâ€invasive prenatal testing for foetal blood groups and implications for <scp>IVD</scp> risk classification according to <scp>EU</scp> regulations. Vox Sanguinis, 2022, 117, 157-165.	0.7	7
2	<i>NM_000148.4(<scp>FUT1</scp>):c.[<scp>229C</scp>>T;<scp>302C</scp>>T]</i> with 2 missense variations in the <scp><i>FUT1</i></scp> gene associated with a paraâ€Bombay phenotype. Transfusion, 2022, 62, E5.	0.8	0
3	Erytra blood group analyser and kode technology testing of SARSâ€CoVâ€2 antibodies among convalescent patients and vaccinated individuals. EJHaem, 2022, 3, 72-79.	0.4	4
4	Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis. Rheumatology, 2022, 61, 2969-2977.	0.9	6
5	A null allele caused by a fourâ€baseâ€pair duplication within the <i>RHCE</i> gene encoding a D– – phenotype. Transfusion, 2021, 61, E23-E25.	0.8	2
6	Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes. Vox Sanguinis, 2021, 116, 141-154.	0.7	3
7	<scp>SCAR</scp> : The highâ€prevalence antigen 013.008 in the <scp>Scianna</scp> blood group system. Transfusion, 2021, 61, 246-254.	0.8	4
8	Modern Rhesus (Rh) typing in transfusion and pregnancy. Cmaj, 2021, 193, E124-E124.	0.9	4
9	<scp>COVID</scp> â€19 antibody screening with <scp>SARSâ€CoV</scp> â€2 red cell kodecytes using routine serologic diagnostic platforms. Transfusion, 2021, 61, 1171-1180.	0.8	13
10	Transfusion support during childbirth for a woman with anti-U and the <i>RHD*weak D type 4.0</i> allele. Immunohematology, 2021, 37, 1-4.	0.2	7
11	Rebound and overshoot of donorâ€specific antibodies to human leukocyte antigens (HLA) during desensitization with plasma exchanges in hematopoietic progenitor cell transplantation: A case report. Transfusion, 2021, 61, 1980-1986.	0.8	7
12	Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome. British Journal of Haematology, 2021, 193, 951-960.	1.2	8
13	Cataloguing experimentally confirmed 80.7Âkb-long ACKR1 haplotypes from the 1000 Genomes Project database. BMC Bioinformatics, 2021, 22, 273.	1.2	1
14	When recombinant proteins can replace rare red cells in immunohematology workups. Transfusion, 2021, 61, 2204-2212.	0.8	2
15	What constitutes the most cautious approach for a pregnant person with weak D type 4.0?. Cmaj, 2021, 193, E916-E916.	0.9	1
16	<i>ABO*B.01+c.464A>C</i> represents a missense variation in the <i>ABO</i> gene and encodes a weak B phenotype. Transfusion, 2021, 61, E59-E61.	0.8	0
17	A practical and effective strategy in East Asia to prevent antiâ€D alloimmunization in patients by C/c phenotyping of serologic RhDâ€negative blood donors. EJHaem, 2021, 2, 750-756.	0.4	4
18	DEL in China: the D antigen among serologic RhD-negative individuals. Journal of Translational Medicine, 2021, 19, 439.	1.8	12

#	Article	IF	Citations
19	HLA associations, somatic loss of HLA expression, and clinical outcomes in immune aplastic anemia. Blood, 2021, 138, 2799-2809.	0.6	23
20	Proceed with care: the "uncommon" serologic weak D phenotypes. Blood Transfusion, 2021, 19, 272-276.	0.3	1
21	COVID-19 Antibody Detection and Assay Performance Using Red Cell Agglutination. Blood, 2021, 138, 1878-1878.	0.6	0
22	COVID-19 Antibody Detection and Assay Performance Using Red Cell Agglutination. Microbiology Spectrum, 2021, 9, e0083021.	1.2	3
23	Frameshift variations in the <scp><i>RHD</i></scp> coding sequence: Molecular mechanisms permitting protein expression. Transfusion, 2020, 60, 2737-2744.	0.8	4
24	<scp><i>NG_007494.1(RHD):c.[4A>T;5G>C;6_7insG]</i></scp> with an <scp>RhD</scp> â€negative phenotype. Transfusion, 2020, 60, E45-E47.	0.8	1
25	ACKR1 Alleles at 5.6 kb in a Well-Characterized Renewable US Food and Drug Administration (FDA) Reference Panel for Standardization of Blood Group Genotyping. Journal of Molecular Diagnostics, 2020, 22, 1272-1279.	1.2	5
26	Preventing transfusionâ€associated graftâ€versusâ€host disease with blood component irradiation: indispensable guidance for a deadly disorder. British Journal of Haematology, 2020, 191, 653-657.	1.2	11
27	The impact of pre-existing HLA and red blood cell antibodies on transfusion support and engraftment in sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation from HLA-matched sibling donors: A prospective, single-center, observational study. EClinicalMedicine, 2020. 24. 100432.	3.2	8
28	It's time to phase out "serologic weak D phenotype―and resolve D types with <i>RHD</i> genotyping including weak D type 4. Transfusion, 2020, 60, 855-859.	0.8	27
29	Group O plasma as a media supplement for CARâ€T cells and other adoptive Tâ€cell therapies. Transfusion, 2020, 60, 1004-1014.	0.8	0
30	COVIDâ€19 insights from transfusion medicine. British Journal of Haematology, 2020, 190, 715-717.	1.2	8
31	A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen alloâ€mmunized patients. British Journal of Haematology, 2020, 189, 551-558.	1.2	17
32	How do you… decide which platelet bacterial risk mitigation strategy to select for your hospitalâ€based transfusion service?. Transfusion, 2020, 60, 675-681.	0.8	4
33	COVID-19: risk of infection is high, independently of ABO blood group. Haematologica, 2020, 105, 2706-2708.	1.7	6
34	<scp>Antiâ€D</scp> immunization rates may exceed 50% in many clinically relevant settings, despite varying widely among patient cohorts. Transfusion, 2020, 60, 1109-1110.	0.8	9
35	An outcome-based review of an accredited Specialist in Blood Banking (SBB) program: 25 years and counting. Immunohematology, 2020, 36, 7-13.	0.2	0
36	DEL. Blood Transfusion, 2020, 18, 159-162.	0.3	6

#	Article	IF	Citations
37	A resource-conserving serologic and highthroughput molecular approach to screen for blood donors with an IN:-5 phenotype. Immunohematology, 2020, 36, 129-132.	0.2	1
38	Immune Hemolysis after a Hematopoietic Progenitor Cell Transplantation for Sickle Cell Disease: A Case Report. Blood, 2020, 136, 20-21.	0.6	0
39	Rapid Engraftment, Immune Recovery, and Resolution of Transfusion Dependence in Treatment-Refractory Severe Aplastic Anemia Following Transplantation with Ex Vivo Expanded Umbilical Cord Blood (Omidubicel). Blood, 2020, 136, 37-38.	0.6	2
40	Does transfusion of Asianâ€type DEL red blood cells to D– recipients cause D alloimmunization?. Transfusion, 2019, 59, 2455-2458.	0.8	6
41	Treatment Strategies for Deficiency of Adenosine Deaminase 2. New England Journal of Medicine, 2019, 380, 1582-1584.	13.9	138
42	Validated Reference Panel from Renewable Source of Genomic DNA Available for Standardization of Blood Group Genotyping. Journal of Molecular Diagnostics, 2019, 21, 525-537.	1.2	7
43	Molecular analysis of the ICAM4 gene in an autochthonous East African population. Transfusion, 2019, 59, 1880-1881.	0.8	2
44	Mosaicism by somatic non-functional mutations: one cell lineage at a time. Haematologica, 2019, 104, 425-427.	1.7	2
45	The phylogeny of 48 alleles, experimentally verified at 21Âkb, and its application to clinical allele detection. Journal of Translational Medicine, 2019, 17, 43.	1.8	2
46	Red Cell Transfusions in the Genomics Era. Seminars in Hematology, 2019, 56, 236-240.	1.8	2
47	International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology: Report of the Dubai, Copenhagen and Toronto meetings. Vox Sanguinis, 2019, 114, 95-102.	0.7	75
48	Inhibition of blood group antibodies by soluble substances. Immunohematology, 2019, 35, 19-22.	0.2	8
49	A proposal for a rational transfusion strategy in patients of European and North African descent with weak D type 4.0 and 4.1 phenotypes. Blood Transfusion, 2019, 17, 89-90.	0.3	14
50	Spectrum and Clinical Significance of HLA Class I Alleles and Their Somatic Mutations in Immune Aplastic Anemia. Blood, 2019, 134, 3738-3738.	0.6	0
51	Inhibition of blood group antibodies by soluble substances. Immunohematology, 2019, 35, 19-22.	0.2	6
52	An update on the Scianna blood group system. Immunohematology, 2019, 35, 48-50.	0.2	2
53	Quality improvement with platelet additive solution for safer out-of-group platelet transfusions. Immunohematology, 2019, 35, 108-115.	0.2	5
54	The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. Seminars in Arthritis and Rheumatism, 2018, 48, 504-512.	1.6	36

#	Article	IF	Citations
55	Transfusion strategy for weak D Type 4.0 based on <i>RHD</i> alleles and <i>RH</i> haplotypes in Tunisia. Transfusion, 2018, 58, 306-312.	0.8	22
56	Two large deletions extending beyond either end of the RHD gene and their red cell phenotypes. Journal of Human Genetics, 2018, 63, 27-35.	1.1	13
57	ABO, Rhesus, and Kell Antigens, Alleles, and Haplotypes in West Bengal, India. Transfusion Medicine and Hemotherapy, 2018, 45, 62-66.	0.7	17
58	Can antiâ€A ₁ cause hemolysis?. Transfusion, 2018, 58, 3036-3037.	0.8	5
59	Two distinct <i>RHCE</i> alleles in cis to <i>weak D type 31</i> alleles in individuals from different ethnicities. Transfusion, 2018, 58, 2465-2466.	0.8	3
60	Long-range haplotype analysis of the malaria parasite receptor gene ACKR1 in an East-African population. Human Genome Variation, 2018, 5, 26.	0.4	12
61	How we evaluate red blood cell compatibility and transfusion support for patients with sickle cell disease undergoing hematopoietic progenitor cell transplantation. Transfusion, 2018, 58, 2483-2489.	0.8	7
62	HNA-3a and HNA-3b antigens among 9 ethnic populations and the Han population in Southwest China. Journal of Translational Medicine, 2018, 16, 67.	1.8	3
63	Analyses of genome wide association data, cytokines, and gene expression in African-Americans with benign ethnic neutropenia. PLoS ONE, 2018, 13, e0194400.	1.1	36
64	Rapid Engraftment and Immune Recovery in Treatment Refractory Severe Aplastic Anemia Patients Undergoing Ex Vivo Nicotinamide-Expanded (NAM-Expanded) Unrelated Cord Blood Transplantation. Blood, 2018, 132, 5789-5789.	0.6	1
65	Molecular immunohaematology round table discussions at the AABB Annual Meeting, Orlando 2016. Blood Transfusion, 2018, 16, 447-456.	0.3	1
66	Serological weak D phenotypes: a review and guidance for interpreting the RhD blood type using the <i><scp>RHD</scp></i> genotype. British Journal of Haematology, 2017, 179, 10-19.	1.2	76
67	Molecular typing for blood group antigens within 40Âmin by direct polymerase chain reaction from plasma or serum. British Journal of Haematology, 2017, 176, 814-821.	1.2	9
68	Acanthocytes in the McLeod phenotype of Xâ€linked chronic granulomatous disease. Transfusion, 2017, 57, 2307-2308.	0.8	6
69	Flashback 1997: collection of hematopoietic progenitor cells by peripheral blood apheresis after stimulation with granulocyte–colonyâ€stimulating factor. Transfusion, 2017, 57, 3067-3068.	0.8	2
70	Red blood cell sedimentation of Apheresis Granulocytes. Transfusion, 2017, 57, 2551-2552.	0.8	2
71	Red cell genotyping precision medicine: a conference summary. Therapeutic Advances in Hematology, 2017, 8, 277-291.	1.1	16
72	Pharmacogenomics Implementation at the National Institutes of Health Clinical Center. Journal of Clinical Pharmacology, 2017, 57, S67-S77.	1.0	19

#	Article	IF	Citations
73	Serologic and molecular characterization of weak D type 29. Transfusion, 2017, 57, 2542-2544.	0.8	4
74	Critical Value Reporting in Transfusion Medicine. American Journal of Clinical Pathology, 2017, 147, 492-499.	0.4	4
75	Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational study. Lancet Haematology,the, 2017, 4, e553-e561.	2.2	24
76	DEL phenotype. Immunohematology, 2017, 33, 125-132.	0.2	25
77	DEL phenotype. Immunohematology, 2017, 33, 125-132.	0.2	15
78	Fullâ€length nucleotide sequences of 30 common <i>SLC44A2</i> alleles encoding human neutrophil antigenâ€3. Transfusion, 2016, 56, 729-736.	0.8	7
79	Red cell alloimmunisation: incidence and prevention. Lancet Haematology,the, 2016, 3, e260-e261.	2.2	2
80	The <i>DAU</i> cluster: a comparative analysis of 18 <i>RHD</i> alleles, some forming partial D antigens. Transfusion, 2016, 56, 2520-2531.	0.8	17
81	International society of blood transfusion working party on red cell immunogenetics and terminology: report of the Seoul and London meetings. ISBT Science Series, 2016, 11, 118-122.	1.1	56
82	Fullâ€length nucleotide sequence of <i>ERMAP</i> alleles encoding Scianna (SC) antigens. Transfusion, 2016, 56, 3047-3054.	0.8	10
83	Transfused neutrophils home to a joint with fungal infection. Transfusion, 2016, 56, 2655-2656.	0.8	1
84	Genotype frequency of human neutrophil antigenâ€3 polymorphisms in the <scp>Y</scp> i, <scp>H</scp> an, and <scp>T</scp> ibetan populations of <scp>C</scp> hina. Transfusion, 2016, 56, 737-742.	0.8	5
85	A genetic marker of the ACKR1 gene is present in patients with Type II congenital smell loss who have type I hyposmia and hypogeusia. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2016, 37, 484-489.	0.6	3
86	Complement Inhibition Using Eculizumab Overcomes Platelet Transfusion Refractoriness in Allo-Immunized Patients Receiving HLA Mismatched Platelets. Blood, 2016, 128, 3840-3840.	0.6	1
87	Immunohematologic Complications after Nonmyeloablative Hematopoietic Progenitor Cell Transplantation in Patients with Sickle Cell Disease. Blood, 2016, 128, 3404-3404.	0.6	0
88	Molecular immunohaematology round table discussions at the AABB Annual Meeting, Anaheim 2015. Blood Transfusion, 2016, 14, 557-565.	0.3	6
89	Implementing massâ€scale red cell genotyping at a blood center. Transfusion, 2015, 55, 2610-2615.	0.8	70
90	The deficiency of adenosine deaminase type 2-results of the rapeutic intervention. Pediatric Rheumatology, 2015, 13, .	0.9	26

#	Article	IF	CITATIONS
91	Transfusion of fresh vs. older red blood cells in the context of infection. ISBT Science Series, 2015, 10, 275-285.	1.1	3
92	Long-Term Immunosuppression After Solitary Islet Transplantation Is Associated With Preserved C-Peptide Secretion for More Than a Decade. American Journal of Transplantation, 2015, 15, 2995-3001.	2.6	13
93	Pathogenesis and mechanisms of antibodyâ€mediated hemolysis. Transfusion, 2015, 55, S47-58.	0.8	74
94	Integration of red cell genotyping into the blood supply chain: a population-based study. Lancet Haematology,the, 2015, 2, e282-e288.	2.2	66
95	Erythrocyte membrane antigen frequencies in patients with Type II congenital smell loss. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2015, 36, 146-152.	0.6	4
96	It's time to phase in <i><scp>RHD</scp></i> genotyping for patients with a serologic weak <scp>D</scp> phenotype. Transfusion, 2015, 55, 680-689.	0.8	157
97	Red Blood Cell Transfusion. JAMA - Journal of the American Medical Association, 2015, 314, 1557.	3.8	37
98	Low frequency of antiâ€D alloimmunization following D+ platelet transfusion: the Antiâ€D Alloimmunization after Dâ€incompatible Platelet Transfusions (ADAPT) study. British Journal of Haematology, 2015, 168, 598-603.	1.2	65
99	Excellent Engraftment and Long-Term Survival in Patients with Severe Aplastic Anemia (SAA) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Haplo-Identical CD34+ Cells Combined with a Single Umbilical Cord Blood Unit. Blood, 2015, 126, 5516-5516.	0.6	2
100	Molecular immunohaematology round table discussions at the AABB Annual Meeting, Denver 2013. Blood Transfusion, 2015, 13, 514-20.	0.3	6
101	Phasing-In RHD Genotyping. Archives of Pathology and Laboratory Medicine, 2014, 138, 585-588.	1.2	19
102	Muddy waters in therapeutic plasma exchange. Transfusion, 2014, 54, 2157-2157.	0.8	5
103	The Rhesus Site. Transfusion Medicine and Hemotherapy, 2014, 41, 357-363.	0.7	68
104	Does prolonged storage of red blood cells cause harm?. British Journal of Haematology, 2014, 165, 3-16.	1.2	99
105	Persistence of recipient human leucocyte antigen (<scp>HLA</scp>) antibodies and production of donor <scp>HLA</scp> antibodies following reduced intensity allogeneic haematopoietic stem cell transplantation. British Journal of Haematology, 2014, 166, 425-434.	1.2	26
106	Genetic variation of the whole <scp><i>ICAM4</i></scp> gene in <scp>C</scp> aucasians and <scp>A</scp> frican <scp>A</scp> mericans. Transfusion, 2014, 54, 2315-2324.	0.8	6
107	International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Cancun report (2012). Vox Sanguinis, 2014, 107, 90-96.	0.7	69
108	A new blood group antigen is defined by antiâ€ <scp>CD</scp> 59, detected in a <scp>CD</scp> 59â€deficient patient. Transfusion, 2014, 54, 1817-1822.	0.8	25

#	Article	IF	Citations
109	Integrating pharmacogenetic information and clinical decision support into the electronic health record. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 522-528.	2.2	61
110	Applying molecular immunohaematology to regularly transfused thalassaemic patients in Thailand. Blood Transfusion, 2014, 12, 28-35.	0.3	36
111	Matching for the D antigen in haematopoietic progenitor cell transplantation: definition and clinical outcomes. Blood Transfusion, 2014, 12, 301-6.	0.3	17
112	Two molecular polymorphisms to detect the (C)ce(s) type 1 haplotype. Blood Transfusion, 2014, 12, 136-7.	0.3	3
113	Molecular immunohaematology round table discussions at the AABB Annual Meeting, Boston 2012. Blood Transfusion, 2014, 12, 280-6.	0.3	10
114	<i><scp>RHD</scp></i> variants in <scp>P</scp> olish blood donors routinely typed as D–. Transfusion, 2013, 53, 2945-2953.	0.8	21
115	<scp>D</scp> category <scp>IV</scp> : a group of clinically relevant and phylogenetically diverse partial <scp>D</scp> . Transfusion, 2013, 53, 2960-2973.	0.8	25
116	Molecular basis of two novel and related highâ€prevalence antigens in the <scp>K</scp> ell blood group system, <scp>KUCI</scp> and <scp>KANT</scp> , and their serologic and spatial association with <scp>K</scp> 11 and <scp>KETI</scp> . Transfusion, 2013, 53, 2872-2881.	0.8	7
117	External quality assessment in molecular immunohematology: the <scp>INSTAND</scp> proficiency test program. Transfusion, 2013, 53, 2850-2858.	0.8	9
118	ABO genotyping: the quest for clinical applications. Blood Transfusion, 2013, 11, 6-9.	0.3	13
119	Allo―and autoantiâ€D in weak D types and in partial D. Transfusion, 2012, 52, 2067-2069.	0.8	9
120	Recommendations for transfusion in ABOâ€incompatible hematopoietic stem cell transplantation. Transfusion, 2012, 52, 456-458.	0.8	35
121	Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test. Vox Sanguinis, 2012, 102, 159-166.	0.7	36
122	Frequencies of <i>SLC44A2</i> alleles encoding human neutrophil antigenâ€3 variants in the African American population. Transfusion, 2012, 52, 1106-1111.	0.8	23
123	Spray: singleâ€donor plasma product for room temperature storage. Transfusion, 2012, 52, 828-833.	0.8	11
124	<i>DARC</i> alleles and Duffy phenotypes in African Americans. Transfusion, 2012, 52, 1260-1267.	0.8	34
125	Peripheral blood stem cell transplant–related <i>Plasmodium falciparum</i> infection in a patient with sickle cell disease. Transfusion, 2012, 52, 2677-2682.	0.8	23
126	Transfusion Clips: a new section for TRANSFUSION. Transfusion, 2012, 52, 1168-1168.	0.8	1

#	Article	IF	Citations
127	Minor Histocompatibility Antigen Mismatch and Incidence of Graft Versus Host Disease, Event-Free, and Overall Survival in Patients Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation. Blood, 2012, 120, 4201-4201.	0.6	0
128	Fresh blood for transfusion: how old is too old for red blood cell units?. Blood Transfusion, 2012, 10, 247-51.	0.3	14
129	118-P Allele frequency assessment of 18 minor histocompatibility antigens (Mhags) in African Americans. Human Immunology, 2011, 72, S97.	1.2	0
130	Molecular genetics and clinical applications for RH. Transfusion and Apheresis Science, 2011, 44, 81-91.	0.5	143
131	Norovirus gastroenteritis causes severe and lethal complications after chemotherapy and hematopoietic stem cell transplantation. Blood, 2011, 117, 5850-5856.	0.6	140
132	International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Berlin report. Vox Sanguinis, 2011, 101, 77-82.	0.7	75
133	Expression of blood group genes by mesenchymal stem cells. British Journal of Haematology, 2011, 153, 520-528.	1.2	31
134	A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for highâ€titer ABO antibodies. Transfusion, 2011, 51, 92-96.	0.8	58
135	Red blood cell preservation by droplet freezing with polyvinylpyrrolidone or sucroseâ€dextrose and by bulk freezing with glycerol. Transfusion, 2011, 51, 2703-2708.	0.8	33
136	Codon usage in vertebrates is associated with a low risk of acquiring nonsense mutations. Journal of Translational Medicine, 2011, 9, 87.	1.8	13
137	SNP Genotyping and LD Testing in ERMAP: Revealing Scianna Blood Group Diversity in NIH Blood Donors. Blood, 2011, 118, 2322-2322.	0.6	5
138	Scianna: the lucky 13th blood group system. Immunohematology, 2011, 27, 25-28.	0.2	12
139	Scianna: the lucky 13th blood group system. Immunohematology, 2011, 27, 41-57.	0.2	9
140	RH genotyping in a sickle cell disease patient contributing to hematopoietic stem cell transplantation donor selection and management. Blood, 2010, 116, 2836-2838.	0.6	45
141	Specific amino acid substitutions cause distinct expression of JAL (RH48) and JAHK (RH53) antigens in RhCE and not in RhD. Transfusion, 2010, 50, 267-269.	0.8	5
142	Organization and management of an accredited specialist in blood bank (SBB) technology program. Transfusion, 2010, 50, 1612-1617.	0.8	14
143	Successful hematopoietic stem-cell transplantation in a patient with chronic granulomatous disease and McLeod phenotype sensitized to Kx and K antigens. Bone Marrow Transplantation, 2010, 45, 209-211.	1.3	13
144	Blutgruppen: Alloantigene auf Erythrozyten. , 2010, , 133-168.		4

#	Article	IF	Citations
145	HLA Alloantibody Persistence and De Novo Production of HLA Alloantibodies of Donor Origin Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation Blood, 2010, 116, 1109-1109.	0.6	0
146	Rare gems: null phenotypes of blood groups. Blood Transfusion, 2010, 8, 2-4.	0.3	17
147	The Bloodgen Project of the European Union, 2003–2009. Transfusion Medicine and Hemotherapy, 2009, 36, 162-167.	0.7	48
148	Genotyping for red blood cell polymorphisms. Vox Sanguinis, 2009, 96, 167-179.	0.7	22
149	International Society of Blood Transfusion Committee on Terminology for Red Blood Cell Surface Antigens: Macao report. Vox Sanguinis, 2009, 96, 153-156.	0.7	65
150	Six years' experience performing <i>RHD</i> genotyping to confirm Dâ^' red blood cell units in Germany for preventing antiâ€D immunizations. Transfusion, 2009, 49, 465-471.	0.8	119
151	D variants at the RhD vestibule in the weak D type 4 and Eurasian D clusters. Transfusion, 2009, 49, 1059-1069.	0.8	39
152	RhCE protein variants in Southwestern Germany detected by serologic routine testing. Transfusion, 2009, 49, 1793-1802.	0.8	22
153	Easy identification of antibodies to highâ€prevalence Scianna antigens and detection of admixed alloantibodies using soluble recombinant Scianna protein. Transfusion, 2009, 49, 2090-2096.	0.8	18
154	Immunogenicity reloaded. Blood, 2009, 114, 3979-3980.	0.6	5
155	DCSâ€1, DCSâ€2, and DFV share amino acid substitutions at the extracellular RhD protein vestibule. Transfusion, 2008, 48, 25-33.	0.8	26
156	Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time. Transfusion, 2008, 48, 2461-2475.	0.8	73
157	Donors with a rare pheno (geno) type. Vox Sanguinis, 2008, 95, 236-253.	0.7	51
158	Blood group A: an overseen risk factor for early-onset ovarian hyperstimulation syndrome?. Reproductive BioMedicine Online, 2008, 17, 185-189.	1.1	23
159	Association of blood group A with early-onset ovarian hyperstimulation syndrome. Transfusion Clinique Et Biologique, 2008, 15, 395-401.	0.2	22
160	Genotyping of Red Blood Cell, Granulocyte and Platelet Antigens: Current Applications in the German-Speaking Countries., 2008, , 189-198.		4
161	A rewarding fresh look at routine blood group data. Blood Transfusion, 2008, 6, 182-3.	0.3	2
162	Will MICA Glitter for Recipients of Kidney Transplants?. New England Journal of Medicine, 2007, 357, 1337-1339.	13.9	4

#	Article	IF	CITATIONS
163	On the Complexity of D Antigen Typing: A Handy Decision Tree in the Age of Molecular Blood Group Diagnostics. Journal of Obstetrics and Gynaecology Canada, 2007, 29, 746-752.	0.3	36
164	Histoblood Groups Other Than HLA in Organ Transplantation. Transplantation Proceedings, 2007, 39, 64-68.	0.3	13
165	International Society of Blood Transfusion Committee on Terminology for Red Cell Surface Antigens: Cape Town report. Vox Sanguinis, 2007, 92, 250-253.	0.7	56
166	The BloodGen project: toward mass-scale comprehensive genotyping of blood donors in the European Union and beyond. Transfusion, 2007, 47, 40S-46S.	0.8	80
167	Blood group genotyping in Germany. Transfusion, 2007, 47, 47S-53S.	0.8	46
168	IVS5â€38del4 deletion in the <i>RHD</i> gene does not cause a DEL phenotype: relevance for <i>RHD</i> alleles including <i>DFRâ€3</i> Transfusion, 2007, 47, 1552-1555.	0.8	15
169	The genetics of the Rhesus blood group system. Blood Transfusion, 2007, 5, 50-7.	0.3	51
170	Molecular genetics ofÂRH andÂitsÂclinical application. Transfusion Clinique Et Biologique, 2006, 13, 4-12.	0.2	71
171	Tissue distribution of blood group membrane proteins beyond red cells: Evidence from cDNA libraries. Transfusion and Apheresis Science, 2006, 35, 71-82.	0.5	17
172	How I manage donors and patients with a weak D phenotype. Current Opinion in Hematology, 2006, 13, 476-483.	1.2	111
173	The D category VI type 4 allele is prevalent in the Spanish population. Transfusion, 2006, 46, 616-623.	0.8	18
174	The RHCE allele ceSL: the second example for D antigen expression without D-specific amino acids. Transfusion, 2006, 46, 766-772.	0.8	23
175	The above letter was also sent to Dr Flegel: Dr Flegel offered the following reply. Transfusion, 2006, 46, 1063-1064.	0.8	8
176	The RHCE allele ceCF: the molecular basis of Crawford (RH43). Transfusion, 2006, 46, 1334-1342.	0.8	31
177	Outliers in RhD membrane integration are explained by variant RH haplotypes. Transfusion, 2006, 46, 1343-1351.	0.8	32
178	An easy RHD genotyping strategy for D? East Asian persons applied to Korean blood donors. Transfusion, 2006, 46, 2128-2137.	0.8	67
179	In-frame triplet deletions in RHD alter the D antigen phenotype. Transfusion, 2006, 46, 2156-2161.	0.8	20
180	Histo-Blood Group Antigens as Allo- and Autoantigens. Annals of the New York Academy of Sciences, 2005, 1050, 40-51.	1.8	22

#	Article	IF	Citations
181	Random survey for RHD alleles among D+ European persons. Transfusion, 2005, 45, 1183-1191.	0.8	56
182	Weak D type 1.1 exemplifies another complexity in weak D genotyping. Transfusion, 2005, 45, 1568-1573.	0.8	21
183	Partial D, weak D types, and novel RHD alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization and prevention. Transfusion, 2005, 45, 1554-1560.	0.8	105
184	SCER and SCAN: two novel high-prevalence antigens in the Scianna blood group system. Transfusion, 2005, 45, 1940-1944.	0.8	22
185	Genetic mechanisms of Rhesus box variation. Transfusion, 2005, 45, 338-344.	0.8	49
186	Homing in on D antigen immunogenicity. Transfusion, 2005, 45, 466-468.	0.8	39
187	RHD Genotyping of Blood Donors May Avoid Anti-D Immunization Blood, 2004, 104, 2706-2706.	0.6	12
188	Review: the molecular basis of the Rh blood group phenotypes. Immunohematology, 2004, 20, 23-36.	0.2	75
189	Blutgruppen: Alloantigene auf Erythrozyten. , 2004, , 145-185.		0
190	Rhesus Box Variation: Multiple RHD Deletion Events and Implications for Testing RHD Heterozygosity Blood, 2004, 104, 2705-2705.	0.6	0
191	Review: the molecular basis of the Rh blood group phenotypes. Immunohematology, 2004, 20, 23-36.	0.2	51
192	The RHCE allele ceRT: D epitope 6 expression does not require D-specific amino acids. Transfusion, 2003, 43, 1248-1254.	0.8	50
193	Antibodies to high-frequency antigens may decrease the quality of transfusion support: an observational study. Transfusion, 2003, 43, 1563-1566.	0.8	68
194	RHD allele distribution in Africans of Mali. BMC Genetics, 2003, 4, 14.	2.7	61
195	Scianna antigens including Rd are expressed by ERMAP. Blood, 2003, 101, 752-757.	0.6	52
196	RHCE represents the ancestral RHposition, while RHD is the duplicated gene. Blood, 2002, 99, 2272-2274.	0.6	40
197	The DAU allele cluster of the RHDgene. Blood, 2002, 100, 306-311.	0.6	82
198	DNB: a partial D with anti-D frequent in Central Europe. Blood, 2002, 100, 2253-2256.	0.6	58

#	Article	IF	CITATIONS
199	Section 1B: Rh flow cytometryCoordinatorË's report.Rhesus index and antigen density: an analysis of the reproducibility of flow cytometric determination. Transfusion Clinique Et Biologique, 2002, 9, 33-42.	0.2	59
200	Medizinisch-naturwissenschaftliche Grundlagen. , 2002, , 87-98.		0
201	Molecular biology of partial D and weak D: implications for blood bank practice. Clinical Laboratory, 2002, 48, 53-9.	0.2	75
202	A new h allele detected in Europe has a missense mutationin alpha(1,2)-fucosyltransferase motif II. Transfusion, 2001, 41, 31-38.	0.8	23
203	PCR screening for common weak D types shows different distributions in three Central European populations. Transfusion, 2001, 41, 45-52.	0.8	104
204	A DV-like phenotype is obliteratedby A226P in the partial D DBS. Transfusion, 2001, 41, 1052-1058.	0.8	18
205	An AQP1 null allele in an Indian woman with Co(a-b-) phenotype and high-titer anti-Co3 associated with mild HDN. Transfusion, 2001, 41, 1273-1278.	0.8	26
206	Completely converting a national blood supply to the use of safer plasma. Transfusion, 2001, 41, 1172b-1172.	0.8	4
207	RHD positive haplotypes in D negative Europeans. BMC Genetics, 2001, 2, 10.	2.7	289
208	Primary anti-D immunization by weak D type 2 RBCs. Transfusion, 2000, 40, 428-434.	0.8	70
209	Predicting a donor's likelihood of donating within a preselected time interval. Transfusion Medicine, 2000, 10, 181-192.	0.5	23
210	RHD gene deletion occurred in the Rhesus box. Blood, 2000, 95, 3662-3668.	0.6	312
211	Weak D alleles express distinct phenotypes. Blood, 2000, 95, 2699-2708.	0.6	223
212	Weak D alleles express distinct phenotypes. Blood, 2000, 95, 2699-708.	0.6	66
213	RHD gene deletion occurred in the Rhesus box. Blood, 2000, 95, 3662-8.	0.6	90
214	Molecular genetics of RH. Vox Sanguinis, 2000, 78 Suppl 2, 109-15.	0.7	10
215	Leukocyte Depletion of Red Cell Components Prevents Exposure of Transfusion Recipients to Neutrophil Elastase. Vox Sanguinis, 2000, 78, 19-27.	0.7	4
216	Molecular Basis of Weak D Phenotypes. Blood, 1999, 93, 385-393.	0.6	317

#	Article	IF	CITATIONS
217	Zinc status in patients with alveolar echinococcosis is related to disease progression. Parasite Immunology, 1999, 21, 237-241.	0.7	19
218	Molecular Basis of Weak D Phenotypes. Blood, 1999, 93, 385-393.	0.6	90
219	An epidemiologic survey of human alveolar echinococcosis in southwestern Germany. Römerstein Study Group American Journal of Tropical Medicine and Hygiene, 1999, 61, 566-573.	0.6	90
220	Molecular basis of weak D phenotypes. Blood, 1999, 93, 385-93.	0.6	70
221	Rh phenotype prediction by DNA typing and its application to practice. Transfusion Medicine, 1998, 8, 281-302.	0.5	77
222	Quality of platelet concentrates. Transfusion, 1998, 38, 799-800.	0.8	0
223	Three Molecular Structures Cause Rhesus D Category VI Phenotypes With Distinct Immunohematologic Features. Blood, 1998, 91, 2157-2168.	0.6	97
224	Three Molecular Structures Cause Rhesus D Category VI Phenotypes With Distinct Immunohematologic Features. Blood, 1998, 91, 2157-2168.	0.6	77
225	Three molecular structures cause rhesus D category VI phenotypes with distinct immunohematologic features. Blood, 1998, 91, 2157-68.	0.6	22
226	Coordinator's report: complement regulatory proteins. Transfusion Clinique Et Biologique, 1997, 4, 117-119.	0.2	2
227	RHD/CE typing by polymerase chain reaction using sequence-specific primers. Transfusion, 1997, 37, 1020-1026.	0.8	108
228	Polymorphism of thehallele and the population frequency of sporadic nonfunctional alleles. Transfusion, 1997, 37, 284-290.	0.8	64
229	Molecular basis of the D variant phenotypes DNU and D II allows localization of critical amino acids required for expression of Rh D epitopes epD3, 4 and 9 to the sixth external domain of the Rh D protein. British Journal of Haematology, 1997, 97, 366-371.	1.2	40
230	RHD antigen density and agglutination in RHD variant red cells. Transfusion Clinique Et Biologique, 1996, 3, 385-386.	0.2	11
231	RHD epitope density profiles of RHD variant red cells analyzed by flow cytometry. Transfusion Clinique Et Biologique, 1996, 3, 429-431.	0.2	24
232	Comparison of Solid-Phase Antibody Screening Tests with Pooled Red Cells in Blood Donors. Vox Sanguinis, 1996, 71, 37-42.	0.7	9
233	Frequencies of the Blood Groups ABO, Rhesus, D Category VI, Kell, and of Clinically Relevant High-Frequency Antigens in South-Western Germany. Transfusion Medicine and Hemotherapy, 1995, 22, 285-290.	0.7	45
234	Low cytokine contamination in buffy coat-derived platelet concentrates without filtration. Transfusion, 1995, 35, 917-920.	0.8	39

#	Article	IF	CITATIONS
235	Transfusion-associated graft-versus-host disease: risk due to homozygous HLA haplotypes. Transfusion, 1995, 35, 284-291.	0.8	74
236	Dpbx, a new homeobox gene closely related to the human proto-oncogene pbxl molecular structure and developmental expression. Mechanisms of Development, 1993, 41, 155-161.	1.7	58
237	Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infection and Immunity, 1993, 61, 5140-5146.	1.0	158
238	Low density lipoproteins inhibit endotoxin activation of monocytes Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992, 12, 341-347.	3.8	42
239	The Role of Lipoproteins in the Inactivation of Endotoxin by Serum. Transfusion Medicine and Hemotherapy, 1992, 19, 202-203.	0.7	6
240	CDw 60 antibodies bind to acetylated forms of ganglioside GD3. Biochemical and Biophysical Research Communications, 1992, 187, 1343-1349.	1.0	44
241	Results of the DGTI Workshop on the Evaluation of the Reactivity of Monoclonal Anti-D. Transfusion Medicine and Hemotherapy, 1992, 19, 12-16.	0.7	0
242	Results of the DGTI workshop on the evaluation of the reactivity of monoclonal anti-D. Beitr \tilde{A} ge Zur Infusionstherapie = Contributions To Infusion Therapy, 1992, 30, 382-7.	0.0	1
243	Stimulation of human T cells via anti-T cell receptor monoclonal antibody BMA031: Distinct cellular events involving interleukin-2 receptor and lymphocyte function antigen 1. Cellular Immunology, 1991, 138, 150-164.	1.4	3
244	Lipopolysaccharide (LPS)-free conditions allow growth and purification of postnatal brain macrophages (microglia). Journal of Immunological Methods, 1989, 116, 147.	0.6	3